Why We Need to Rethink Ethnicity-Based Genetic Testing
By Shivani Nazareth,
US News & World Report
| 11. 07. 2016
A recent study noted racial bias in the genetic databases that are important to furthering research in precision medicine. The data is skewed toward a European Caucasian population, which makes it difficult to interpret genetic variants in minority groups. As the U.S. population increasingly diversifies, we need to challenge ourselves to do better. A good place to begin is pregnancy, when nearly every woman in the U.S. is offered genetic carrier screening.
Carrier screening is the practice of testing of both mom and dad for inherited conditions that may be passed along to their baby. A pregnant woman is typically offered screening – for one condition, a few conditions or a panel – based upon her self-reported ethnic category. As an example, black patients are offered screening for sickle cell disease, Southeast Asian patients for thalassemias and Ashkenazi Jewish patients for a panel that includes Canavan and Tay-Sachs disease, among others. This approach is based on a public health model that factors cost and the availability of a reliable test into the screening equation. In the past few...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...